The Phacilitate Advanced Therapies Europe 2022 conference will take place from 30 August to 1 September at the Royal Lancaster in London, UK. The conference is the European twin to Phacilitate Advanced Therapies Week, an event held in January in Florida, US.
The event is tailored to a European audience looking to commercialise ATMPs globally, as well as a global audience looking to understand and expand into the European market. More than 80 speakers will be giving talks across four content tracks on critical issues that the gene therapy sector is facing. Here are a few of many discussions and events to earmark.
How CAR-T became synonymous with commercial success
Emily Whitehead became the first child in the world to receive the revolutionary cell therapy treatment named CAR-T in 2012 as a last hope to cure her of leukaemia – she remains in remission 10 years later. From within the cell and gene community, Emily’s story and the scientific and commercial success of CAR-T are well known, but the wider public’s awareness is growing along with the potential of the therapy.
Chaired by Anthony Davies, Founder & CEO of Dark Horse Consulting, this panel discussion with speakers from the Emily Whitehead Foundation, the Children’s Hospital of Philadelphia’s Cell & Gene Therapy Lab, Novartis and Oxford Biomedica unpacks CAR-T’s end-to-end story, looking back at its success journey and looking ahead to the future possibilities and applications.
Improving patient experience within clinical trials and long term follow up
Through a variety of case study presentations chaired by Dr Stephan Grupp, Medical Director of the Cell & Gene Therapy Lab at the Children’s Hospital of Philadelphia, focus is placed on improving patient experience through drug development pathways using treat-NMD network as well as CTL019 in paediatric ALL, where a 17-year-old with refractory ALL completes 10 years of CAR-T follow up.
Attendees can be part of the conversation by participating in this year’s roundtables. This will be a platform to debate the challenges, discuss the opportunities and discover the solutions to the most pressing challenges within cell and gene therapies with peers. The roundtables include, but are not limited to:
1. Operational excellence within manufacturing: Commercalisation vs cost
Moderator: Frank Thielmann, Head Lean – Global Operational Excellence, Takeda
2. The importance of brand stratefy & development in your commercialisation journey
Moderator: Steve Bloodworth, Head of Commercial Partnering & Martech Deployment, AstraZeneca
3. Raw & starting materials for ATMP’s: ensuring quality, reliability and speed
Moderators: Alexandre Reeber, CEO, Core Biogenesis and Daniel Cermeno, Product Manager, Core Biogenesis
4. Creating a sustainable cell & gene therapy company
Moderator: Joel Eichmann, Co-founder, Green Elephant Biotech
5. Challenge and barriers to move from 2D to stirred 3D systems
Moderator: Giovanni Lorenzon, Bioprocess Specialist, Eppendorf
6. Patient engagement during clinical development: keeping the “customer” in mind
Moderator: Kai Pinkernell, Chief Medical Officer, Glycostem